Will Repligen stock go up?

According to Danelfin AI, Repligen has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (45.19%) is -5.63% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Repligen stock?

The Repligen target price is $166.32 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Repligen stock right now?

Repligen has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (45.19%) is -5.63% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Repligen stock is a good buy .

Is Repligen undervalued right now?

Based on analysts, the average price target upside for Repligen is +19.64% (1Y). According to Danelfin AI, Repligen has today an AI Score of 3/10 (Sell Rating).

What was the price range of Repligen stock over the past 12 months?

The Repligen stock price range over the past 12 months has been $102.87 - $172.26.

What is going on with Repligen stock in the last 3 months?

The Repligen stock performance in the last quarter has been +17.99%.

Does Repligen offer dividend payments?

No, Repligen does not currently pay dividends.

What is the current market capitalization of Repligen?

Repligen's market cap is $7.84B, as of 2026-07-02 08:00.

When is the next RGEN earnings report date?

RGEN will publish its next earnings report on 2026-05-05.

Repligen Corp (RGEN) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

RGEN AI-Powered Stock Analysis

AI Score Explanation

AI Score

Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Repligen Corp today receives an AI Score of 3/10, which translates to a Sell rating. The stock has a 45% probability of outperforming the market in the next 3 months, which is 6% lower than the average probability of any stock (51%). Among the top positive contributors, the Chart Pattern (252d) adds +0.57% to the probability, while Earnings Countdown (52 days since earnings) and Gross Profit (in the top 50%) each contribute +0.55%. On the negative side, the Industry (Life Sciences Tools & Services) is the top detractor, reducing probability by -3.54%, followed by the Fear & Greed Index (value 31, indicating fear) at -0.91%, and the Chart Pattern (90d) at -0.68%. Notable data points include the ATR (14d Volatility) in the top 10% (value 6.75), which detracts -0.58% due to high volatility, and Maximum Volatility in the top 30% (value 6.06), also a detractor at -0.54%. On the positive side, Tangible Shareholders' Equity ranks in the top 30% (value $630.4M) and adds +0.48%, while Analyst Mean Price Target Upside (30.4% upside) is in the top 50% and contributes +0.38%. Overall, the stock faces strong headwinds from its industry and market sentiment, outweighing the positive signals from earnings timing and profitability, resulting in a below-average probability and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Profitability+0.55%
Profitability and operating efficiency metrics
Growth+0.35%
Expected pace of revenue and earnings expansion
Size & Liquidity+0.28%
Company size and trading liquidity
Valuation+0.16%
How the stock is priced relative to its fundamentals

Sentiment-4.13%
How analysts and the market view the stock
Momentum-1.43%
Direction and strength of recent price movements
Volatility-1.41%
How much the stock price tends to fluctuate

RGEN probability advantage of beating the market (3M):

-5.63%

AI Score

Sell

Repligen (RGEN) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -5.63% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of RGEN (45.19%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
RGEN probability advantage of beating the market (3M)-5.63%
RGEN probability of beating the market (3M)45.19%

RGEN probability advantage of beating the market (3M): -5.63%

The AI-powered overall analysis of Repligen (RGEN) is based on the 29 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of RGEN:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Life Sciences Tools & Services	N/A	-3.54%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.91%
Technical	Chart Pattern (90d)	figure_147	N/A	-0.68%
Technical	ATR (14d Volatility)	6.75		-0.58%
Technical	Chart Pattern (252d)	figure_24	N/A	+0.57%
Technical	Chart Pattern (180d)	figure_140	N/A	-0.55%
Sentiment	Earnings Countdown	-52		+0.55%
Fundamental	Gross Profit	108.28		+0.55%
Technical	Maximum Volatility	6.06%		-0.54%
Technical	Chart Pattern (504d)	figure_17	N/A	-0.53%
Fundamental	Upgrade to unlock			+0.48%
Fundamental	Upgrade to unlock			-0.39%
Sentiment	Upgrade to unlock			+0.38%
Sentiment	Upgrade to unlock			-0.38%
Sentiment	Upgrade to unlock			-0.37%

Rest of Alpha Signals: +0.31%

RGEN probability advantage of beating the market (3M)Total:-5.63%
RGEN AI Score

Significant changes Vs previous day

RGEN Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$139.02
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

RGEN Proven Sell Signal & Price Forecast

This is the price chart for RGEN from January 2, 2026 until today. The chart indicates, in red, the 55 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

RGEN Average Past Performance & Loss Rate

Three months after its 417 Sell signals since July 2026, RGEN had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

417 Past RGEN Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+19.93%
Average Alpha				+4.18%
Loss Rate (% Negative Perf.)				35.31%
% Negative Alpha				51.04%

RGEN Frequently Asked Questions

Will Repligen stock go up?
According to Danelfin AI, Repligen has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (45.19%) is -5.63% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Repligen stock?
Is it a good time to buy, sell, or hold Repligen stock right now?
Is Repligen undervalued right now?
What was the price range of Repligen stock over the past 12 months?
What is going on with Repligen stock in the last 3 months?
Does Repligen offer dividend payments?
What is the current market capitalization of Repligen?
When is the next RGEN earnings report date?

Repligen Corp Company Profile

Repligen Corporation is a global leader in advancing bioprocessing technologies and systems. The company’s primary operations focus on revamping biological drug manufacturing procedures, with an expansive reach across North America, Europe, Asia Pacific, and beyond.

One of Repligen's key offerings includes Protein A ligands - the integral components in Protein A affinity chromatography resins – alongside an array of cell culture growth factor products. The firm's innovative approach to chromatography is exemplified through its trademarked OPUS pre-packed chromatography columns. These tools play a critical role in refining biologics by simplifying protein isolation processes. Furthermore, their scaled-down counterparts facilitate numerous functions such as high-throughput process development screening, viral clearance validation studies, and scale-down validation of chromatography protocols.

Under the CaptivA brand, Repligen extends its offering to include resilience-boosting chromatography resins. The company also has a stake in filtration solutions – its XCell Alternating Tangential Flow systems have notably revolutionized upstream perfusion and cell culture processing methods.

Other flagship filtrations solutions include TangenX flat sheet cassettes for downstream biologic drug concentration and buffer exchange procedures, KrosFlo Tangential Flow Filtration along with depth filtration systems, and Spectra/Por lab/process dialysis products consolidated under ProConnex TFDF flow paths.

In line with its relentless pursuit of innovation, Repligen offers process analytics solutions like pioneering slope spectroscopy systems under SoloVPE, FlowVPE and FlowVPX brands. Repligen courts a vast network of clientele comprising life sciences entities, biopharmaceutical firms, diagnostics companies and laboratory research bodies alongside contract manufacturing organizations.

Beyond providing services and products, the company has strategically aligned itself with Navigo Proteins GmbH on multiple affinity ligand development projects that are poised to forge new frontiers within the industry. Since its establishment in 1981, Repligen Corporation bears the hallmark of innovation and excellence out of its headquarters located in Waltham, Massachusetts.

Sector:Health Care
Country:United States
Industry:
Address:Building 1, Suite 100, 41 Seyon Street, Waltham
Employees:2,000
Website:repligen.com

Pros

High customer switching costs in bioprocessing workflows

Structural growth in the global biologics market

Recurring revenue from consumable bioprocessing products

Proprietary technology in filtration and chromatography

Operating leverage from specialized component manufacturing

Cons

Customer concentration risk among biopharmaceutical manufacturers

Pros

Cons

Company

AI Score

Compare

AMGNAmgen Inc

TECHBio-Techne Corp

REPLReplimune Group Inc

PGENPrecigen Inc

LCTXLineage Cell Therapeutics Inc

Company

AI Score

Compare

	Company	AI Score	Compare
1	QSIQuantum-Si Inc
2	QGENQiagen NV
3	MXCTMaxCyte Inc
4	STVNStevanato Group SpA
5	MLABMesa Laboratories Inc
6	SEERSeer Inc
7	EVOEvotec SE
8	NAUTNautilus Biotechnology Inc
9	ICLRICON PLC
10	LABStandard BioTools Inc

Company

AI Score

Compare

QSIQuantum-Si Inc

QGENQiagen NV

MXCTMaxCyte Inc

STVNStevanato Group SpA

MLABMesa Laboratories Inc

SEERSeer Inc

EVOEvotec SE

NAUTNautilus Biotechnology Inc

ICLRICON PLC

LABStandard BioTools Inc

Company

AI Score

Compare

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc

Company

AI Score

Compare

COGTCogent Biosciences Inc

Company

AI Score

Compare

RGEN Stock AI Analysis

Repligen Corp

RGEN Stock AI Analysis

Repligen Corp

RGEN AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

RGEN probability advantage of beating the market (3M): -5.63%

RGEN Short Trading Parameters

RGEN Proven Sell Signal & Price Forecast

RGEN Average Past Performance & Loss Rate

RGEN Frequently Asked Questions

Will Repligen stock go up?

What is the target price for Repligen stock?

Is it a good time to buy, sell, or hold Repligen stock right now?

Is Repligen undervalued right now?

What was the price range of Repligen stock over the past 12 months?

What is going on with Repligen stock in the last 3 months?

Does Repligen offer dividend payments?

What is the current market capitalization of Repligen?

When is the next RGEN earnings report date?

Repligen Corp Company Profile

Pros

Cons

Pros

Cons

RGEN Company Profile Summary

RGEN Related Investment Themes

RGEN Related Stocks

RGEN Top 10 Industry Stocks

Life Sciences Tools & Services

RGEN Top 10 Sector Stocks

Health Care

RGEN Stock AI Analysis

Repligen Corp

NASDAQ NMS - GLOBAL MARKET

Will Repligen stock go up?

What is the target price for Repligen stock?

Is it a good time to buy, sell, or hold Repligen stock right now?

Is Repligen undervalued right now?

What was the price range of Repligen stock over the past 12 months?

What is going on with Repligen stock in the last 3 months?

Does Repligen offer dividend payments?

What is the current market capitalization of Repligen?

When is the next RGEN earnings report date?

Pros

Cons

AI Score Explanation

NASDAQ NMS - GLOBAL MARKET

RGEN Proven Sell Signal & Price Forecast